Abstract
Anti-tissue transglutaminase, previously held to be identical to anti-endomysial antibodies in celiac sprue, has been reported in inflammatory bowel disease patients. To investigate these data further, we evaluated serum and intestinal anti-tissue transglutaminase in inflammatory bowel disease patients, with respect to the Crohn’s disease activity index and the integrated disease activity index. Study population comprised: 49 patients with Crohn’s disease and 29 patients with ulcerative colitis; 45 patients with celiac sprue and 85 autoimmune patients as disease controls; and 58 volunteers as healthy controls. Immunoglobulin A (IgA) anti-recombinant human tissue transglutaminase and anti-endomysial antibody detection in sera and fecal supernatants were performed. Adsorption of positive sera with recombinant human tissue transglutaminase were also performed. Marked increased anti-tissue transglutaminase concentrations were found in celiac sprue, while low-positive values were also found in Crohn’s disease and ulcerative colitis. Anti-endomysial antibodies were detectable only in celiac sprue. Antigen adsorption resulted in a significant reduction of the anti-tissue transglutaminase either in celiac sprue or inflammatory bowel disease sera. A significant correlation between anti-tissue transglutaminase and Crohn’s disease activity index or integrated disease activity index scores was found. Anti-tissue transglutaminase was also detectable in fecal supernatants from inflammatory bowel disease patients. Data highlight that both circulating and intestinal anti-tissue transglutaminases are detectable in inflammatory bowel disease, and that they are related to disease activity. These features underline that, in addition to anti-tissue transglutaminase, an anti-endomysial antibody test is necessary in the diagnostic work-up of celiac sprue, especially in patients with known inflammatory bowel disease.
References
1 Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. Fed Am Soc Exp Biol J 1991; 5:3071–7.10.1096/fasebj.5.15.1683845Search in Google Scholar
2 Piacentini M. Tissue transglutaminase: a candidate effector element of physiological cell death. Curr Top Microbiol Immunol 1995; 200:163–75.10.1007/978-3-642-79437-7_12Search in Google Scholar
3 Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 7:797–801.10.1038/nm0797-797Search in Google Scholar
4 Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001; 120:636–51.10.1053/gast.2001.22123Search in Google Scholar
5 Sulkanen S, Halttunen T, Laurila K, Kolho KL, Korponay-Szabo IR, Sarnesto A, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998; 115:1322–8.10.1016/S0016-5085(98)70008-3Search in Google Scholar
6 Koop I, Ilchmann R, Izzi L, Adragna A, Koop H, Barthelmes H. Detection of autoantibodies against tissue transglutaminase in patients with celiac disease and dermatitis herpetiformis. Am J Gastroenterol 2000; 95:2009–14.10.1111/j.1572-0241.2000.02086.xSearch in Google Scholar
7 Farrace MG, Picarelli A, Di Tola M, Sabbatella L, Marchione OP, Ippolito G, et al. Presence of anti-“tissue” transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event? Cell Death Diff 2001; 8:767–70.10.1038/sj.cdd.4400880Search in Google Scholar
8 Carroccio A, Vitale G, Di Prima L, Chifari N, Napoli S, La Russa C, et al. Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clin Chem 2002; 48:1546–50.10.1093/clinchem/48.9.1546Search in Google Scholar
9 Picarelli A, Sabbatella L, Di Tola M, Di Cello T, Vetrano S, Anania MC. Antiendomysial antibody detection in fecal supernatants: in vivo proof that small bowel mucosa is the site of antiendomysial antibody production. Am J Gastroenterol 2002; 97:95–8.10.1111/j.1572-0241.2002.05426.xSearch in Google Scholar
10 Malchow H, Ewe K, Brandes JV, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249–66.10.1016/0016-5085(84)90409-8Search in Google Scholar
11 Lockart-Mummery HE, Morson BC. Crohn’s disease of the large intestine and its distinction from ulcerative colitis. Gut 1960; 1:87–105.10.1136/gut.1.2.87Search in Google Scholar
12 Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index (CDAI). Gastroenterology 1979; 77:843–6.10.1016/0016-5085(79)90384-6Search in Google Scholar
13 Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87:971–6.Search in Google Scholar
14 Walker-Smith JA, Guandalini S, Schmitz J, Shmerling DH, Visakorpi JK. Revisedcriteria for diagnosis of celiac disease. Arch Dis Child 1990; 65:909–11.Search in Google Scholar
15 Vecchi M, Folli C, Donato MF, Formenti S, Arosio E, De Franchis R. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand J Gastroenterol 2003; 38:50–4.10.1080/00365520310000438Search in Google Scholar PubMed
16 Peracchi M, Trovato C, Longhi M, Gasparin M, Conte D, Tarantino C, et al. Tissue transglutaminase antibodies in patients with end-stage heart failure. Am J Gastroenterol 2002; 97:2850–4.10.1111/j.1572-0241.2002.07033.xSearch in Google Scholar PubMed
17 Picarelli A, Di Tola M, Sabbatella L, Vetrano S, Anania MC, Spadaro A, et al. Anti-tissue transglutaminase antibodies in arthritic patients: a disease-specific event? Clin Chem 2003; 49:2091–4.10.1373/clinchem.2003.023234Search in Google Scholar PubMed
18 Carroccio A, Giannitrapani L, Soresi M, Not T, Iacono G, Di Rosa C, et al. Guinea pig transglutaminase immuno-linked assay does not predict celiac disease in patients with chronic liver disease. Gut 2001; 49:506–11.10.1136/gut.49.4.506Search in Google Scholar PubMed PubMed Central
19 Marttinen A, Maki M. Purification of fibroblast-derived celiac disease auto-antigen molecules. Pediatr Res 1993; 34:420–3.10.1203/00006450-199310000-00007Search in Google Scholar PubMed
20 Borner H, Osman AA, Meergans T, Weiske T, Mothes T. Isolation of antigens recognized by celiac disease auto-antibodies and their use in enzyme immunoassay of endomysium and reticulin antibody-positive human sera. Clin Exp Immunol 1996; 106:344–50.10.1046/j.1365-2249.1996.d01-850.xSearch in Google Scholar PubMed PubMed Central
21 Lock J, Gilmour JEM, Unsworth DJ. Anti-tissue transglutaminase, anti-endomysium and anti-R1-reticulin auto-antibodies, the antibody trinity of coeliac disease. Clin Exp Immunol 1999; 116:258–62.10.1046/j.1365-2249.1999.00909.xSearch in Google Scholar PubMed PubMed Central
22 Uhlig HH, Lichtenfeld J, Osman AA, Richter T, Mothes T. Evidence for existence of celiac disease autoantigens apart from tissue transglutaminase. Eur J Gastroenterol Hepatol 2000; 12:1017–20.10.1097/00042737-200012090-00009Search in Google Scholar PubMed
23 Stulik J, Hernychova L, Porkertova S, Pozler O, Tuckova L, Sanchez D, et al. Identification of new celiac disease autoantigens using proteomic analysis. Proteomics 2003; 3:951–6.10.1002/pmic.200300370Search in Google Scholar PubMed
24 Korponay-Szabo IR, Laurila K, Szondy Z, Halttunen T, Szalai Z, Dahlbom I, et al. Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. Gut 2003; 52:199–204.10.1136/gut.52.2.199Search in Google Scholar PubMed PubMed Central
25 D’Argenio G, Biancone L, Cosenza V, Della Valle N, D’Armiento FP, Boirivant M, et al. Transglutaminases in Crohn’s disease. Gut 1995; 37:690–5.10.1136/gut.37.5.690Search in Google Scholar PubMed PubMed Central
© Walter de Gruyter
